Capricor Therapeutics (FRA:4LN2) 5-Year EBITDA Growth Rate : 26.00% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics 5-Year EBITDA Growth Rate?

Capricor Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.29.

During the past 3 years, the average EBITDA Per Share Growth Rate was 0.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Capricor Therapeutics was 76.10% per year. The lowest was -208.40% per year. And the median was 13.10% per year.

Competitive Comparison of Capricor Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Capricor Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's 5-Year EBITDA Growth Rate falls into.

Capricor Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Capricor Therapeutics (FRA:4LN2) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Capricor Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (FRA:4LN2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CAPR:USA

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines